首页> 外文期刊>Lab on a chip >Sensitive tear screening of diabetic retinopathy with dual biomarkers enabled using a rapid electrokinetic patterning platform
【24h】

Sensitive tear screening of diabetic retinopathy with dual biomarkers enabled using a rapid electrokinetic patterning platform

机译:使用快速电动图案化平台启用双生物标志物的糖尿病视网膜病变的敏感撕裂筛查

获取原文
获取原文并翻译 | 示例
           

摘要

Bead-based immunosensors have intrigued the scientific community over the past decades due to their rapid and multiplexed capabilities in the detection of various biological targets. Nevertheless, their use in the detection of low-abundance analytes remains a continuing challenge because of their limited number of active enrichment approaches. To this end, our research presents a delicate microbead enrichment technique using an optoelectrokinetic platform, followed by the detection of dual biomarkers for the sensitive screening of an eye disease termed diabetic retinopathy (DR). In this study, microbeads turned fluorescent as their surfaces formed sandwiched immunocomplexes in the presence of target antigens. The tiny fluorescent dots were then concentrated using the optoelectrokinetic platform for the enhancement of their signals. The signal rapidly escalated in 10 s, and the optimal limit of detection was nearly 100 pg mL(-1). For practical DR screening, two biomarkers, lipocalin 1 (LCN1) and vascular endothelial growth factor (VEGF), were used. Approximately 20 mu L of analytes were collected from the tear samples of the tested patients. The concentrations of both biomarkers showed escalating trends with the severity of DR. Two concentration thresholds of LCN1 and VEGF that indicate proliferative DR were determined out of 24 clinical samples based on the receiver operating characteristic curves. For verification, a single-blind test was conducted with additional clinical tear samples from five random subjects. The final outcome of this evaluation showed an accuracy of >80%. This non-invasive screening provides a potential means for the early diagnosis of DR and may increase the screening rate among the high-risk diabetic population in the future.
机译:由于其在检测各种生物学目标的迅速和多路复用能力,珠子的免疫传感器在过去几十年中感兴趣。然而,由于其有限数量的活性富集方法,它们在检测到低丰度分析物中的使用仍然是一个持续的挑战。为此,我们的研究呈现了一种使用光电平台的微妙的微珠富集技术,然后检测了双生物标志物,用于对眼病称为糖尿病视网膜病变(DR)的敏感筛查。在本研究中,微珠转动荧光,因为它们的表面形成夹层的免疫复合在靶抗原的存在下。然后使用光电平台浓缩微小的荧光点以提高它们的信号。在10秒内快速升级的信号,检测的最佳极限将近100pg ml(-1)。对于实际的DR筛选,使用两种生物标志物,脂质化1(LCN1)和血管内皮生长因子(VEGF)。从测试患者的撕裂样品中收集约20μL的分析物。两种生物标志物的浓度显示出博士的严重程度的趋势。基于接收器操作特征曲线,从24个临床样本中确定了24个临床样品的LCN1和VEGF的两个浓度阈值。为了验证,通过来自五个随机对象的另外的临床撕样样品进行单盲试验。该评估的最终结果显示了> 80%的准确性。这种非侵入性筛选提供了对DR的早期诊断的潜在手段,并且可以在未来增加高风险糖尿病群的筛选率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号